HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.

Abstract
High-dose, continuous infusion interleukin-2 (IL-2) regimens generate greater Lymphokine Activated Killer cell (LAK) cytotoxicity in vitro and a higher rebound lymphocytosis in vivo than do bolus IL-2 regimens. Lymphocytes initially activated by continuous infusion IL-2 then subsequently pulsed with IL-2 have increased cytotoxicity against cancer cells. Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes. Fourteen patients with melanoma were treated with famotidine 20 mg intravenously twice per day and continuous infusion IL-2 (18 MIU/sq m/24 hours) for 72 hours, followed by a 24-hour rest, then IL-2 18 MIU/sq m over 15-30 minutes for 1 dose (12 patients) or daily for 3 doses (2 patients). Most common toxicities were fever, nausea/emesis, hypophosphatemia, hypomagnesemia, and rigors. Nine partial responses (64% response rate; 95% Confidence Interval: 39%-84%) have been seen. Median survival has not been reached at greater than 10 months. Two patients responding to therapy showed an increase in detectable CD 56(+) cells in serial subcutaneous or lymph node biopsies, while 1 patient undergoing progression of disease had no such infiltrate. High-dose, 72-hour continuous infusion plus pulse interleukin-2 with famotidine has activity in melanoma. CD 56(+) cells may play a role in responding patients.
AuthorsWalter Quan, Maria Ramirez, W Chris Taylor, Mikhail Vinogradov, Nawazish Khan, Shawn Jackson
JournalCancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 19 Issue 6 Pg. 770-5 (Dec 2004) ISSN: 1084-9785 [Print] United States
PMID15665626 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Interleukin-2
  • Famotidine
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage)
  • Bone Neoplasms (drug therapy, secondary)
  • Drug Therapy, Combination
  • Famotidine (administration & dosage)
  • Female
  • Humans
  • Infusions, Intravenous
  • Interleukin-2 (administration & dosage)
  • Liver Neoplasms (drug therapy, secondary)
  • Lung Neoplasms (drug therapy, secondary)
  • Lymph Nodes
  • Male
  • Melanoma (drug therapy)
  • Middle Aged
  • Pulse
  • Skin Neoplasms (drug therapy)
  • T-Lymphocytes, Cytotoxic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: